NEW YORK, Feb. 12, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Roka Bioscience, Inc. ("Roka" or the "Company") (Nasdaq:ROKA) securities between July 17, 2014 and November 6, 2014.
Click here to learn about the case: http://docs.wongesq.com/ROKA-Info-Request-Form-607. There is no cost or obligation to you.
The complaint alleges that Roka's initial public offering documents failed to disclose known trends and uncertainties about the decline in demand for its Atlas instruments.
On November 6, 2014, Roka announced a net loss of $0.64 per share in the third quarter of 2014. The Company also acknowledged it had not placed any Atlas instruments in that quarter.
If you suffered a loss in Roka you have until February 23, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email firstname.lastname@example.org, by telephone at 212.425.1140, or visit http://docs.wongesq.com/ROKA-Info-Request-Form-607.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: email@example.comSource:The Law Offices of Vincent Wong